156 related articles for article (PubMed ID: 28961677)
1. Performance of a Validated Risk Score to Predict HIV-1 Acquisition Among African Women Participating in a Trial of the Dapivirine Vaginal Ring.
Balkus JE; Brown ER; Palanee-Phillips T; Matovu Kiweewa F; Mgodi N; Naidoo L; Mbilizi Y; Jeenarain N; Gaffoor Z; Siva S; Nair G; Pather A; Baeten JM
J Acquir Immune Defic Syndr; 2018 Jan; 77(1):e8-e10. PubMed ID: 28961677
[No Abstract] [Full Text] [Related]
2. Greater dapivirine release from the dapivirine vaginal ring is correlated with lower risk of HIV-1 acquisition: a secondary analysis from a randomized, placebo-controlled trial.
Brown ER; Hendrix CW; van der Straten A; Kiweewa FM; Mgodi NM; Palanee-Philips T; Marzinke MA; Bekker LG; Soto-Torres L; Hillier SL; Baeten JM;
J Int AIDS Soc; 2020 Nov; 23(11):e25634. PubMed ID: 33206462
[TBL] [Abstract][Full Text] [Related]
3. Reasons for nonadherence to the dapivirine vaginal ring: narrative explanations of objective drug-level results.
Montgomery ET; Stadler J; Naidoo S; Katz AWK; Laborde N; Garcia M; Reddy K; Mansoor LE; Etima J; Zimba C; Chitukuta M; Soto-Torres L
AIDS; 2018 Jul; 32(11):1517-1525. PubMed ID: 29957723
[TBL] [Abstract][Full Text] [Related]
4. Evaluating the potential impact and cost-effectiveness of dapivirine vaginal ring pre-exposure prophylaxis for HIV prevention.
Reidy M; Gardiner E; Pretorius C; Glaubius R; Torjesen K; Kripke K
PLoS One; 2019; 14(6):e0218710. PubMed ID: 31242240
[TBL] [Abstract][Full Text] [Related]
5. Clinical and Virologic Outcomes Following Initiation of Antiretroviral Therapy Among Seroconverters in the Microbicide Trials Network-020 Phase III Trial of the Dapivirine Vaginal Ring.
Riddler SA; Balkus JE; Parikh UM; Mellors JW; Akello C; Dadabhai S; Mhlanga F; Ramjee G; Mayo AJ; Livant E; Heaps AL; O'Rourke C; Baeten JM;
Clin Infect Dis; 2019 Jul; 69(3):523-529. PubMed ID: 30346511
[TBL] [Abstract][Full Text] [Related]
6. Relationship Type and Use of the Vaginal Ring for HIV-1 Prevention in the MTN 020/ASPIRE Trial.
Pleasants E; Tauya T; Reddy K; Mirembe BG; Woeber K; Palanee-Phillips T; Zimba C; Atujuna M; Montgomery ET;
AIDS Behav; 2020 Mar; 24(3):866-880. PubMed ID: 31111297
[TBL] [Abstract][Full Text] [Related]
7. Development of dapivirine vaginal ring for HIV prevention.
Devlin B; Nuttall J; Wilder S; Woodsong C; Rosenberg Z
Antiviral Res; 2013 Dec; 100 Suppl():S3-8. PubMed ID: 24188702
[TBL] [Abstract][Full Text] [Related]
8. HIV Prevention: Opportunities and Challenges.
Marrazzo JM
Top Antivir Med; 2017; 24(4):123-126. PubMed ID: 28208119
[TBL] [Abstract][Full Text] [Related]
9. Use of the dapivirine vaginal ring and effect on cervical cytology abnormalities.
Reddy K; Kelly C; Brown ER; Jeenarain N; Naidoo L; Siva S; Bekker LG; Nair G; Makanani B; Chinula L; Mgodi N; Chirenje Z; Kiweewa FM; Marrazzo J; Bunge K; Soto-Torres L; Piper J; Baeten JM; Palanee-Phillips T;
AIDS; 2020 Mar; 34(4):559-567. PubMed ID: 31764068
[TBL] [Abstract][Full Text] [Related]
10. Pre-clinical development of a combination microbicide vaginal ring containing dapivirine and darunavir.
Murphy DJ; Desjardins D; Dereuddre-Bosquet N; Brochard P; Perrot L; Pruvost A; Le Grand R; Lagatie O; Vanhooren L; Feyaerts M; van Roey J; Malcolm RK
J Antimicrob Chemother; 2014 Sep; 69(9):2477-88. PubMed ID: 24862093
[TBL] [Abstract][Full Text] [Related]
11. Brief Report: Dapivirine Vaginal Ring Use Does Not Diminish the Effectiveness of Hormonal Contraception.
Balkus JE; Palanee-Phillips T; Reddy K; Siva S; Harkoo I; Nakabiito C; Kintu K; Nair G; Chappell C; Kiweewa FM; Kabwigu S; Naidoo L; Jeenarain N; Marzinke M; Soto-Torres L; Brown ER; Baeten JM
J Acquir Immune Defic Syndr; 2017 Oct; 76(2):e47-e51. PubMed ID: 28542081
[TBL] [Abstract][Full Text] [Related]
12. Impact of Partner-Related Social Harms on Women's Adherence to the Dapivirine Vaginal Ring During a Phase III Trial.
Palanee-Phillips T; Roberts ST; Reddy K; Govender V; Naidoo L; Siva S; Gafoor Z; Pather A; Matovu F; Hlahla K; Makanani B; Nair G; Schwartz K; Torjesen K; Brown E; Soto-Torres L; Baeten J; Montgomery ET
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):580-589. PubMed ID: 30239426
[TBL] [Abstract][Full Text] [Related]
13. Pregnancy and Infant Outcomes Among Women Using the Dapivirine Vaginal Ring in Early Pregnancy.
Makanani B; Balkus JE; Jiao Y; Noguchi LM; Palanee-Phillips T; Mbilizi Y; Moodley J; Kintu K; Reddy K; Kabwigu S; Jeenariain N; Harkoo I; Mgodi N; Piper J; Rees H; Scheckter R; Beigi R; Baeten JM
J Acquir Immune Defic Syndr; 2018 Dec; 79(5):566-572. PubMed ID: 30383589
[TBL] [Abstract][Full Text] [Related]
14. Use of a Vaginal Ring Containing Dapivirine for HIV-1 Prevention in Women.
Baeten JM; Palanee-Phillips T; Brown ER; Schwartz K; Soto-Torres LE; Govender V; Mgodi NM; Matovu Kiweewa F; Nair G; Mhlanga F; Siva S; Bekker LG; Jeenarain N; Gaffoor Z; Martinson F; Makanani B; Pather A; Naidoo L; Husnik M; Richardson BA; Parikh UM; Mellors JW; Marzinke MA; Hendrix CW; van der Straten A; Ramjee G; Chirenje ZM; Nakabiito C; Taha TE; Jones J; Mayo A; Scheckter R; Berthiaume J; Livant E; Jacobson C; Ndase P; White R; Patterson K; Germuga D; Galaska B; Bunge K; Singh D; Szydlo DW; Montgomery ET; Mensch BS; Torjesen K; Grossman CI; Chakhtoura N; Nel A; Rosenberg Z; McGowan I; Hillier S;
N Engl J Med; 2016 Dec; 375(22):2121-2132. PubMed ID: 26900902
[TBL] [Abstract][Full Text] [Related]
15. Hygiene, Blood Flow, and Vaginal Overload: Why Women Removed an HIV Prevention Vaginal Ring During Menstruation in Malawi, South Africa, Uganda and Zimbabwe.
Duby Z; Katz AWK; Browne EN; Mutero P; Etima J; Zimba CC; Woeber K; Atujuna M; Reddy K; van der Straten A;
AIDS Behav; 2020 Feb; 24(2):617-628. PubMed ID: 31030301
[TBL] [Abstract][Full Text] [Related]
16. Adherence and Acceptability of a Multidrug Vaginal Ring for HIV Prevention in a Phase I Study in the United States.
van der Straten A; Panther L; Laborde N; Hoesley CJ; Cheng H; Husnik MJ; Horn S; Nel A; Soto-Torres L; Chen BA
AIDS Behav; 2016 Nov; 20(11):2644-2653. PubMed ID: 26837628
[TBL] [Abstract][Full Text] [Related]
17. Brief Report: Anal Intercourse, HIV-1 Risk, and Efficacy in a Trial of a Dapivirine Vaginal Ring for HIV-1 Prevention.
Peebles K; van der Straten A; Palanee-Phillips T; Reddy K; Hillier SL; Hendrix CW; Harkoo I; Gati Mirembe B; Jeenarain N; Baeten JM; Brown ER;
J Acquir Immune Defic Syndr; 2020 Mar; 83(3):197-201. PubMed ID: 31809308
[TBL] [Abstract][Full Text] [Related]
18. Correlates of Adherence to the Dapivirine Vaginal Ring for HIV-1 Prevention.
Husnik MJ; Brown ER; Dadabhai SS; Gaffoor Z; Jeenarain N; Kiweewa FM; Livant E; Mansoor LE; Mirembe BG; Palanee-Phillips T; Singh D; Siva S; Soto-Torres L; van der Straten A; Baeten JM;
AIDS Behav; 2021 Sep; 25(9):2801-2814. PubMed ID: 34117592
[TBL] [Abstract][Full Text] [Related]
19. Assessing Per-Sex-Act HIV-1 Risk Reduction Among Women Using the Dapivirine Vaginal Ring.
Stalter RM; Dong TQ; Hendrix CW; Palanee-Phillips T; van der Straten A; Hillier SL; Kiweewa FM; Mgodi NM; Marzinke MA; Bekker LG; Soto-Torres L; Baeten JM; Brown ER;
J Infect Dis; 2024 Apr; 229(4):1158-1165. PubMed ID: 38099506
[TBL] [Abstract][Full Text] [Related]
20. [PrEP (pre-exposure prophylaxis) for women: what are the benefits of the vaginal ring?].
Oberhofer E
MMW Fortschr Med; 2016 Jun; 158 Suppl 1():11. PubMed ID: 27259891
[No Abstract] [Full Text] [Related]
[Next] [New Search]
